looking good, page-15

Bone Medical continues to rapidly secure patents in key, high value markets. Last month the company announced it has been granted the Axcess II patent in Japan just a day after it revealed it had been awarded an Axcess IV patent in Russia for CaPTHymone, an oral parathyroid hormone for osteoporosis.

The Axcess II patent has already been granted or approved for grant in the U.S., Russia, Japan and several other countries.

The Axcess III patent has been granted or approved for grant in Australia, China, India, New Zealand and Europe.

The Axcess IV patent has been granted in New Zealand and Australia.

http://www.proactiveinvestors.com.au/companies/news/30927/bone-medical-extends-patent-position-of-oral-bone-disease-treatment-in-key-japanese-market-30927.html